Drug–Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis Infection Catia MarzoliniSara GibbonsSaye Khoo Commentary 14 December 2021 Pages: 339 - 346
Clinical Pharmacokinetics and Pharmacodynamics of Roxadustat David CzockFrieder Keller Review Article Open access 14 December 2021 Pages: 347 - 362
Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin Kyle C. MolinaMatthew A. MillerTyree H. Kiser Review Article 21 December 2021 Pages: 363 - 374
Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling Maiara Camotti MontanhaFrancesc FabregaMarco Siccardi Original Research Article Open access 12 October 2021 Pages: 375 - 386
Population Pharmacokinetic Modeling of Inebilizumab in Subjects with Neuromyelitis Optica Spectrum Disorders, Systemic Sclerosis, or Relapsing Multiple Sclerosis Li YanHolly KimkoWilliam A. Rees Original Research Article Open access 31 October 2021 Pages: 387 - 400
Pre- and Postnatal Maturation are Important for Fentanyl Exposure in Preterm and Term Newborns: A Pooled Population Pharmacokinetic Study Yunjiao WuSwantje VöllerCatherijne A. J. Knibbe Original Research Article Open access 13 November 2021 Pages: 401 - 412
Comparison of Pharmacokinetics and Pharmacodynamics of Inhaled Technosphere Insulin and Subcutaneous Insulin Lispro in the Treatment of Type 1 Diabetes Mellitus Marshall GrantTim HeiseRobert Baughman Original Research Article Open access 13 November 2021 Pages: 413 - 422
The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition Amina BensalemGuillaume CartronDavid Ternant Original Research Article 13 November 2021 Pages: 423 - 437
Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis Paul van den BergMartijn RuppertThomas Eissing Original Research Article Open access 13 November 2021 Pages: 439 - 450
Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria Sebastiaan Camiel GouloozeNelleke SnelderThomas Eissing Original Research Article Open access 17 November 2021 Pages: 451 - 462
Correction to: Clinical Investigation on Endogenous Biomarkers to Predict Strong OAT-Mediated Drug–Drug Interactions Marie-Emilie WilleminThomas K. Van Der MadeJan Snoeys Correction 17 February 2022 Pages: 463 - 463